AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca 
Welcome,         Profile    Billing    Logout  
 1 Disease   6 Trials   6 Trials   1006 News 


«123456789101112»
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Alexion Pharma
    Journal:  Request for an Andexxa Value Analysis. (Pubmed Central) -  Nov 2, 2020   
    Based on the safety and efficacy concerns of andexanet alfa, a value statement in and or as an addendum to society guidelines is vital considering the high cost of therapy. In this era of ever-increasing health care costs, every clinician, health system, national society, insurer, and pharmaceutical company should work to be good stewards of our society's resources.
  • ||||||||||  Xarelto (rivaroxaban) / J&J, Bayer
    [VIRTUAL] Self-inflicted Trauma After Rivaroxaban Overdose () -  Oct 17, 2020 - Abstract #ASA2020ASA_755;    
    The ICU course was further complicated by DKA, retained hemothorax, and aspiration. He was transferred to acute care on hospital day 22 in stable condition.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Alexion Pharma
    Reimbursement, Journal, HEOR:  Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage. (Pubmed Central) -  Oct 10, 2020   
    The projected cost of andexanet would exceed the national average hospital reimbursement/patient in nearly 75% of patients by over $7500/hospitalization. 4F-PCC was significantly less expensive, had lower rates of thrombosis, but also lower rates of good/excellent hemostasis compared to published data for andexanet.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Alexion Pharma
    [VIRTUAL] There Will be Blood: A Cautionary Tale of Triple Therapy (OnDemand) -  Oct 10, 2020 - Abstract #AHA2020AHA_5166;    
    The pericardial pressure improved from 24 mmHg to 4 mmHg with complete resolution of the patient’s shock and neurological deficits. Our case demonstrates the risks associated with triple antithrombotic therapy as well as the nuanced clinical decision-making and risk-benefit assessment required when considering the use of anticoagulant reversal agents to prevent bleeding complications in the context of recent ischemic events and the need for urgent invasive procedures.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Alexion Pharma
    [VIRTUAL] Cost utility analysis of andexanet alfa for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage () -  Oct 8, 2020 - Abstract #ASHP2020ASHP_333;    
    Our analysis suggests that using andexanet alfa to treat ICH associated with DOACs is cost effective compared to the use of PCCs. Findings are robust to deterministic and probabilistic sensitivity analysis, and are largely driven by the lower mortality risk and improved functional outcomes of andexanet alfa compared to PCCs in this model.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Alexion Pharma
    [VIRTUAL] Real-world hemostatic effectiveness of andexanet alfa for management of intracerebral hemorrhage () -  Oct 8, 2020 - Abstract #ASHP2020ASHP_314;    
    Twelve ICH patients (median age 86 years, 66.7% men, 66.7% received apixaban, 33.3% rivaroxaban and 91.7% had atrial fibrillation) were included. In oFXaI patients experiencing ICH, andexanet alfa resulted in a high rate of hemostatic effectiveness and decreased hematoma volumes.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Alexion Pharma
    [VIRTUAL] Exhibitor Symposium: Portola - Andexxa (coagulations factor Xa (recombinant), inactivated-zhzo) () -  Sep 21, 2020 - Abstract #AAST2020AAST_370;    
    Learning Objectives: Identify reversal management options for patients with Factor Xa inhibitor related bleeding. Speakers: Alan Brockhurst, MD, Trauma Medical Director, Sarasota Memorial Hospital Moderator: Sebastian D. Schubl, MD, FACS Irvine, CA USA Register at www.hlxregister.com refer to program code: RT2LE2
  • ||||||||||  Journal:  Analysis of anticoagulation reversal survey (ARES). (Pubmed Central) -  Sep 20, 2020   
    However, only 58.7% used the labeled dose of 4-PCC for warfarin reversal...In addition, the majority of respondents utilized idarucizumab for dabigatran reversal. The only involvement activity in which <50% of respondents said they were frequently involved or always involved was 'administration of reversal agent.' There is considerable variability in which agents were utilized for anticoagulant-associated bleeding reversal.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Alexion Pharma
    [VIRTUAL] Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) () -  Sep 19, 2020 - Abstract #NCS2020NCS_446;    
    Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Sep 2020 | Trial primary completion date: Nov 2022 --> Sep 2020 Supported by: ALEXION
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Alexion Pharma
    Journal:  Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. (Pubmed Central) -  Sep 4, 2020   
    In the ANNEXA-4 study, treatment with andexanet was associated with a 92% reduction in median anti-Xa activity levels and excellent or good hemostasis in 82% of patients presenting with serious bleeding while receiving apixaban or rivaroxaban. In this review, we discuss the burden of bleeding in anticoagulated patients and the need for reversal agents, review the mechanism of action of andexanet and critically evaluate the evidence for its efficacy and safety.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Alexion Pharma
    Journal:  Andexanet Alfa: Considerations and Practical Applications. (Pubmed Central) -  Sep 1, 2020   
    In this review, we discuss the burden of bleeding in anticoagulated patients and the need for reversal agents, review the mechanism of action of andexanet and critically evaluate the evidence for its efficacy and safety. No abstract available
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Alexion Pharma
    Clinical, Review, Journal:  Institutional Experience of Using Andexanet Alfa. (Pubmed Central) -  Aug 18, 2020   
    Anticoagulation was never started in all patients. This review tends to show the real-world utilization data of andexanet in a community hospital setting.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Enrollment change:  Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor (clinicaltrials.gov) -  Aug 8, 2020   
    P4,  N=900, Recruiting, 
    This review tends to show the real-world utilization data of andexanet in a community hospital setting. N=440 --> 900
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Clinical, Journal, Real-world evidence:  Real-world utilization of andexanet alfa. (Pubmed Central) -  Aug 2, 2020   
    There were no thrombotic complications. Yet, larger and comparative studies are needed to clarify the optimal agent and patient selection for reversal of factor Xa inhibitors.
  • ||||||||||  Review, Journal:  Antidotes for reversal of direct oral anticoagulants. (Pubmed Central) -  Jul 29, 2020   
    Ciraparantag, has potential to reverse the anticoagulant activity of multiple agents. The pharmacology, preclinical, and clinical data that have developed these specific antidotes are reviewed in this manuscript.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Alexion Pharma
    Clinical, Journal, Real-World Evidence:  Real-world utilization of andexanet alfa. (Pubmed Central) -  Jul 29, 2020   
    The pharmacology, preclinical, and clinical data that have developed these specific antidotes are reviewed in this manuscript. No abstract available
  • ||||||||||  Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Alexion Pharma, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim
    Journal:  The Diagnosis and Treatment of Acute Traumatic Bleeding and Coagulopathy. (Pubmed Central) -  Jul 9, 2020   
    The evidence-based treatment of patients with hemorrhage from severe trauma, in accordance with the existing guidelines, can improve the clinical outcome. Corresponding algorithms, adapted to local logistics and infrastructure, must be developed and implemented.
  • ||||||||||  simvastatin / Generic mfg.
    [VIRTUAL] Spontaneous Non-Traumatic Subdural Intra-Spinal Thoracolumbar Hematoma Secondary to Standard Apixiban Dose for Atrial Fibrillation, Resulting in Acute Bilateral Lower Extremity Flaccid Paralysis (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_6951;    
    We present a case involving a non-traumatic spontaneous subdural intra-spinal thoracolumbar hematoma in a patient on standard atrial fibrillation dosing of apixiban, who developed progressive bilateral lower extremity flaccid paralysis, requiring Andexanet alfa and laminectomy nerve decompression...Medications were notable for aspirin, apixiban at 5 mg twice daily, lisinopril, and simvastatin...Anticoagulation was held post-operatively and the patient was continued on lisinopril, metoprolol, and atorvastatin in the ICU for further evaluation and monitoring...This uncommon case signifies the importance of anticoagulation evaluation, and the monitoring of standard apixiban dosing for atrial fibrillation, even without trauma or procedural provocation. Furthermore, diagnosis is challenging and requires a high level of clinical suspicion due to possible irreversible neurological impairment.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma
    Journal:  Reply to "Key Points to Consider When Evaluating Andexxa for Formulary Addition". (Pubmed Central) -  Jun 28, 2020   
    Furthermore, diagnosis is challenging and requires a high level of clinical suspicion due to possible irreversible neurological impairment. No abstract available
  • ||||||||||  Retrospective data, Review, Journal:  The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis. (Pubmed Central) -  Jun 15, 2020   
    Specific antidotes (idarucizumab for dabigatran and andexanet alfa for FXa inhibitors) and hemostatic reversal agents were used for lowering bleeding, but their efficacies were still uncertain...In conclusion, specific reversal agents might be useful for reversal of bleeding and lowering the risk of death than standard reversal agents. Our findings were based on case reports/series and selected cohorts, further comparative studies are thus needed.
  • ||||||||||  Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim
    Journal:  What we have learned about direct oral anticoagulant reversal. (Pubmed Central) -  Jun 11, 2020   
    Importantly, patients with DOAC-related major bleeding have substantial short-term risks of thrombosis and mortality, emphasizing the need for individualized patient assessment and protocolized bleed management strategies that include assessment of candidacy for safe resumption of OACs. With expanding indications and increasing prevalence of DOAC-eligible patients, bleeding complications and their management represent an ever-greater major health problem.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma
    Journal:  Andexanet alfa: the best antidote for factor Xa inhibitors? (Pubmed Central) -  May 21, 2020   
    With the recent approval by the European Medicines Agency (EMA) but unknown Dutch reimbursement status, the role of andexanet for daily clinical practice in the Netherlands remains to be determined. Notably, and importantly, when treating patients with anticoagulant-associated major bleeding, local haemostatic control and-if relevant-adequate fluid resuscitation are at least as important as choosing the optimal anticoagulation antidote.